

*Fellow Registrars,*

*We at MCR hope you have a blessed holiday season and wish you a happy, healthy 2023! We look forward to collaborating with you in the new year.*

## **DUE DATES**

To be on track, large hospitals (>500 cases/yr.) typically would be expected to have abstracted July 2022 diagnosis cases by January 15, 2023. Smaller facilities (<300 cases /yr.) would be expected to have reported the 2nd Quarter of 2022 by January 15, 2023. We will be monitoring reporting timeliness and completeness *closely* in 2023.

## **EDUCATION**

### **MCR Help-Line**

Reach us at 1-800-392-2829 during regular office hours or leave a message; a member of our QA team will return your call within one business day.

### **FLccSC-New Course Available!**

Earn 3 CE's

NAACCR Webinar “**Esophagus 2022**” presented December 2022.

### **Breast 2022 Part 2 Streaming Link:**

The FLccSC link for the NAACCR Webinar “**Breast 2022 part 2**” presented November 2022 has been corrected. If you had trouble with the streaming link in FLccSC it has been updated.

### **NAACCR Webinar:**

#### **NAACCR Webinar: Head and Neck 2023**

January 12, 2023 8-11 a.m., This webinar will cover the anatomy, solid tumor rules, staging and treatment of Head & Neck cancers. Examples, quizzes, and case scenarios included. To attend the live broadcast in Columbia, Mo, sign up here: <https://www.signupgenius.com/go/30E0E4BA9A823A6FB6-naacccr18>

### **Visitor Parking at Parking Structure 7 (PS7) for NAACCR Webinars**

Only those with a valid PS7 visitor permission pass will be allowed to park there. A daily visitor permit is \$7 for parking in lots and \$9 for parking garages. Violators are subject to ticketing and towing.

You can purchase a visitor pass online at <https://missouri.nupark.com/v2/Portal/Login>

### **NAACCR Webinar:**

#### **V23 Update: ICD O, Solid Tumor Rules, SSDI**

January 11, 2023 12-2 p.m. Central Time, This webinar will cover updates to histology codes, Solid Tumor Rules, and the SSDI rules. We will review new terms, changes in behavior, and new histologies that will be implemented with diagnosis year 2023. We will look at changes to the Solid Tumor Manual and new and updated SSDI's. The webinar is free of charge. We will apply to NCRA for 2 CEs. Sign up for the webinar at: [https://naacccr.zoom.us/webinar/register/WN\\_-frlMGW0SJ-v5o8l1--Cw](https://naacccr.zoom.us/webinar/register/WN_-frlMGW0SJ-v5o8l1--Cw)

### **NAACCR CTR Prep and Review Series January 2023**

The **NAACCR CTR Exam Preparation and Review Webinar Series** offers online interactive instruction with live instructors. The course includes eight 2-hour sessions carefully prepared to reflect the changes to the 2023 CTR exam. A subscription is \$195 per participant. Only one person may participate per subscription. The series includes 8 weekly "live" lectures presented by experience instructors. Q&A sessions, study materials, weekly online quizzes and a timed practice test during our last session. The last day of the course is the Tuesday before the start of the exam. If a participant is unable to attend one of the live sessions, they may view the recording at their convenience. The next session will begin on January 10, 2023. Check the NAACCR website for additional information at <https://education.naacr.org/ctr>

### **Solid Tumor Rules: 2023 Update**

The **2023 Other Sites Rules** have undergone comprehensive revisions and have been posted on the SEER Website. The 2023 consolidated pdf is now available for download for use beginning with cases diagnosed 1/1/2023 forward. It is important to review the 2023 change log to see what revisions have been made. The updated Solid Tumor Rules may be accessed at: <https://seer.cancer.gov/tools/solidtumor/>

### **SEER\*Educate**

**Cancer Registry Management 4<sup>th</sup> Edition Textbook**, Newly released multiple choice tests under training, CTR Prep. The updated 4<sup>th</sup> edition of this publication is currently used by many of the college programs preparing students for the registry profession. Category A CEs available, and more!

Log in or sign up at **SEER\*Educate** today by visiting <https://educate.fredhutch.org/> and Learn by Doing!

## **Help Desk will be CLOSED Dec 23-26 & Dec 31-Jan 2**

## **MCR NEWS**

### **Abstract Plus**

MCR is in the process of **phasing out** Abstract Plus. For those who use Abstract Plus currently, we will assist you with transitioning to using Web Plus. Abstract Plus will still be available to use for historical data and generating reports at your facility. Web Plus is internet based, therefore, takes the additional task of upgrading away from the end user. Low volume facilities will need to report 2022 cases via Web Plus. If you are ready to start abstracting 2022 cases, please contact me so we can get you started on Web Plus.

### **Holiday Closings**

The MCR office will be closed December 26-January 2. Please leave your messages on our help line (1-800-392-2829) and we will get back to you when we return.

## **ABSTRACTING TIP**

Changes to the Grade Manual, version 2.1 in ***all Grade Path Tables***

Table 5: Changes to Grade Manual, Version 2.1

Grade Table #	Sites Included	Original Text	Updated Text
All	Grade Path Tables	<p><b>Note :</b> Use the grade from the <b>clinical work up</b> from the primary tumor in different scenarios based on behavior or surgical resection</p> <ul style="list-style-type: none"> <li>• Behavior: <ul style="list-style-type: none"> <li>○ Tumor behavior for the clinical and the pathological diagnoses are the same AND the clinical grade is the highest grade</li> <li>○ Tumor behavior for clinical diagnosis is invasive, and the tumor behavior for the pathological diagnosis is in situ</li> </ul> </li> <li>• Surgical Resection <ul style="list-style-type: none"> <li>○ Surgical resection is done of the primary tumor and there is no grade documented from the surgical resection</li> <li>○ Surgical resection is done of the primary tumor and there is no residual cancer</li> <li>○ Surgical resection of the primary tumor has not</li> </ul> </li> </ul>	<p><b>Note :</b> Use the grade from the <b>clinical work up</b> from the primary tumor in different scenarios based on behavior or surgical resection</p> <ul style="list-style-type: none"> <li>• Behavior: <ul style="list-style-type: none"> <li>○ Tumor behavior for the clinical and the pathological diagnoses are the same AND the clinical grade is the highest grade</li> <li>○ Tumor behavior for clinical diagnosis is invasive, and the tumor behavior for the pathological diagnosis is in situ</li> </ul> </li> <li>• Surgical Resection <ul style="list-style-type: none"> <li>○ Surgical resection is done of the primary tumor and there is no grade documented from the surgical resection</li> <li>○ Surgical resection is done of the primary tumor and there is no residual cancer</li> <li>○</li> </ul> </li> <li>• <b>No Surgical Resection</b> <ul style="list-style-type: none"> <li>○ Surgical resection of the primary tumor has not been done, but there is positive confirmation of distant metastases during the clinical time frame</li> </ul> </li> </ul>

**New bullet:** When there is **No Surgical Resection** – Surgical resection of primary tumor has not been done, but there is microscopic confirmation of distant metastasis during the clinical time frame.

**Grade Pathological** may include the grade from the clinical workup, as all information from diagnosis (clinical staging) through the surgical resection is used for pathological staging.

**Example 1:** Lung biopsy shows PD Adenocarcinoma. Liver biopsy shows PD Adenocarcinoma. There is no surgical resection of primary site, but there is positive microscopic confirmation of distant metastasis during the clinical time frame.

Grade Clinical – 3

Grade Pathological – 3

**Example 2:** Liver biopsy shows MD Adenocarcinoma, Pancreas Primary. There was no biopsy of the primary site in the pancreas.

Grade Clinical – 9

Grade Pathological – 9

(Grade Clinical and Grade Pathological would be 9 because you have no grade from the primary site)

## NEWS FROM THE STANDARD SETTERS

### Casefinding list

The FY 2023 ICD-10-CM Casefinding list can be found at <https://seer.cancer.gov/tools/casefinding/>

## **COC**

The October 2022 CANSWER Forum webinar reviewed STORE 2023 data items and the methods registrars should use to collect data items when abstracting a case. The link to register for this course can be found at [https://www.facs.org/for-medical-professionals/news-publications/news-and-articles/cancer-programs-news/120122/october-2022-canswer-forum-live-recording-now-available/?utm\\_campaign=cancernews-12012022&utm\\_medium=email&utm\\_source=newsletter](https://www.facs.org/for-medical-professionals/news-publications/news-and-articles/cancer-programs-news/120122/october-2022-canswer-forum-live-recording-now-available/?utm_campaign=cancernews-12012022&utm_medium=email&utm_source=newsletter)

## **REGISTRY TO RESEARCH**

Primary Brain and Other CNS Tumors Diagnosed in the US From 2015 to 2019 (NCI)  
[https://academic.oup.com/neuro-oncology/article/24/Supplement\\_5/v1/6742201?login=true](https://academic.oup.com/neuro-oncology/article/24/Supplement_5/v1/6742201?login=true)

## **RESOURCES AND ITEMS OF INTEREST**

Axillary Radiotherapy vs Axillary Lymph Node Dissection for Sentinel Node–Positive Breast Cancer  
<https://ascopubs.org/doi/10.1200/JCO.22.01565>

Overall Survival With ctDNA-Guided Therapy in Advanced NSCLC  
<https://www.nature.com/articles/s41591-022-02047-z>

Cancer Deaths Due to COVID-19 Explored in March to December 2020  
<https://jamanetwork.com/journals/jamaoncology/fullarticle/2797015>

Triplet Therapy as a Treatment Option for Patients With Metastatic Castration-Sensitive Prostate Cancer  
<https://www.sciencedirect.com/science/article/abs/pii/S107814392200391X?via%3Dihub>

Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab Therapy in Patients With Advanced NSCLC  
[https://www.practiceupdate.com/c/145351/1/1/?elsca1=emc\\_eneews\\_expert-insight&elsca2=email&elsca3=practiceupdate\\_onc&elsca4=oncology&elsca5=newsletter&rid=NTEyMjg3Njg4NDYOS0&lid=20844084](https://www.practiceupdate.com/c/145351/1/1/?elsca1=emc_eneews_expert-insight&elsca2=email&elsca3=practiceupdate_onc&elsca4=oncology&elsca5=newsletter&rid=NTEyMjg3Njg4NDYOS0&lid=20844084)

Incidence Proportion and Prognosis of Leptomeningeal Disease Among Patients With Breast vs Non-Breast Primaries  
<https://academic.oup.com/neuro-oncology/advance-article-abstract/doi/10.1093/neuonc/noac249/6823872?redirectedFrom=fulltext&login=true>

Trastuzumab Deruxtecan Extends Survival Over Chemotherapy for Patients With HER2-Positive Metastatic Breast Cancer  
[https://www.practiceupdate.com/c/145865/67/13/?elsca1=emc\\_eneews\\_weekinreview&elsca2=email&elsca3=practiceupdate\\_metastaticbreastcancer&elsca4=metastaticbreastcancer&elsca5=newsletter&rid=NTEyMjg3Njg4NDYOS0&lid=20849614](https://www.practiceupdate.com/c/145865/67/13/?elsca1=emc_eneews_weekinreview&elsca2=email&elsca3=practiceupdate_metastaticbreastcancer&elsca4=metastaticbreastcancer&elsca5=newsletter&rid=NTEyMjg3Njg4NDYOS0&lid=20849614)

Smoking Duration, Intensity Tied to Bladder Cancer Recurrence  
<https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2799072>

*“The only impossible journey is the one you never begin” – Tony Robbins*